Dive Brief: Merck & Co. disclosed Monday afternoon that it is pausing enrollment in two studies of its checkpoint inhibitor Keytruda (pembrolizumab) due to patient deaths. KEYNOTE-183 and KEYNOTE-185 will not recruit any further patients based on a recommendation from an external data monitoring committee. The two multiple myeloma studies are testing Keytruda in combination and Merck...